FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer By Ogkologos - September 19, 2025 627 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Cohort 2 of SunRISe-1 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Excellence in cancer research nursing: Celebrating innovation during tough times October 7, 2022 FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine... July 29, 2026 Breast Cancer Death Rates Will Rise in Elderly EU Patients but... March 12, 2025 EMA Recommends to Extend Therapeutic Indications for Crizotinib in Paediatric Patients July 26, 2024 Load more HOT NEWS Women Diagnosed with Early Breast Cancer Since 2000 Have About a... The Combination of Nivolumab and Cabozantinib Provides a New First-Line Treatment... Research with Integrity – integrating training into research culture Low Risk of Cardiotoxicity with Immune Checkpoint Inhibitor Monotherapy or Combination...
